Levobetaxolol
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Levobetaxolol
|
|
| Systematic (IUPAC) name | |
| (S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C18H29NO3 |
| Mol. mass | 342.472 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | topical (ophthalmic) |
Levobetaxolol or Levobetxolol hydrochloride is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker.
[edit] Effect
Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.
[edit] Contraindications and side effects
Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.
The drug has been associated with bradycardia and hypertension.
|
|||||||||||
|
||||||||||||||||||||
